ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparison of 20-core Versus 12-core Prostate Biopsy Diagnostic Performance in the Detection of Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00992615
Recruitment Status : Completed
First Posted : October 9, 2009
Last Update Posted : August 29, 2012
Sponsor:
Information provided by:
Poitiers University Hospital

Brief Summary:
The optimal number of prostate cores extracted during a prostate biopsy performed because of a suspected prostate cancer is still debated. The present consensus is to sample 12 cores. However, recent data published in the literature brought arguments in favour of a higher number, probably 20. This would have the advantages of decreasing the false negatives and the re-biopsy rate.

Condition or disease Intervention/treatment Phase
Prostate Cancer Procedure: prostate biopsy Not Applicable

Study Type : Interventional  (Clinical Trial)
Official Title: Comparison of 20-core vs 12-core Prostate Biopsy Diagnostic Performance in the Detection of Prostate Cancer

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: Arm 20 cores Procedure: prostate biopsy
prostate cores - 12 or 20
Active Comparator: arm 12 cores Procedure: prostate biopsy
prostate cores - 12 or 20




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Criteria

Inclusion Criteria:

  • Patients older than 18
  • Patients with a PSA value between 3 et 20 ng/ml
  • Obtained informed consent
  • Patients able to comply with the study protocol
  • Patients covered by a social insurance

Exclusion Criteria:


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00992615


Locations
France
service d'Urologie - CHU de Poitiers - 2 rue de la Milétrie
Poitiers, France, 86021
Sponsors and Collaborators
Poitiers University Hospital

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00992615     History of Changes
Other Study ID Numbers: BP20-12
First Posted: October 9, 2009    Key Record Dates
Last Update Posted: August 29, 2012
Last Verified: November 2009

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases